Literature DB >> 26560685

Infectious Complications Following Small Bowel Transplantation.

J T Silva1, R San-Juan1, B Fernández-Caamaño2, G Prieto-Bozano2, M Fernández-Ruiz1, C Lumbreras1, J Calvo-Pulido3, C Jiménez-Romero3, E Resino-Foz1, F López-Medrano1, M Lopez-Santamaria4, J Maria Aguado1.   

Abstract

Microbiological spectrum and outcome of infectious complications following small bowel transplantation (SBT) have not been thoroughly characterized. We performed a retrospective analysis of all patients undergoing SBT from 2004 to 2013 in Spain. Sixty-nine patients underwent a total of 87 SBT procedures (65 pediatric, 22 adult). The median follow-up was 867 days. Overall, 81 transplant patients (93.1%) developed 263 episodes of infection (incidence rate: 2.81 episodes per 1000 transplant-days), with no significant differences between adult and pediatric populations. Most infections were bacterial (47.5%). Despite universal prophylaxis, 22 transplant patients (25.3%) developed cytomegalovirus disease, mainly in the form of enteritis. Specifically, 54 episodes of opportunistic infection (OI) occurred in 35 transplant patients. Infection was the major cause of mortality (17 of 24 deaths). Multivariate analysis identified retransplantation (hazard ratio [HR]: 2.21; 95% confidence interval [CI]: 1.02-4.80; p = 0.046) and posttransplant renal replacement therapy (RRT; HR: 4.19; 95% CI: 1.40-12.60; p = 0.011) as risk factors for OI. RRT was also a risk factor for invasive fungal disease (IFD; HR: 24.90; 95% CI: 5.35-115.91; p < 0.001). In conclusion, infection is the most frequent complication and the leading cause of death following SBT. Posttransplant RRT and retransplantation identify those recipients at high risk for developing OI and IFD. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  (allograft) function; clinical research; dysfunction; infectious; infectious disease; intestinal; intestinal disease; intestine; malignant; multivisceral transplantation; practice

Mesh:

Year:  2015        PMID: 26560685     DOI: 10.1111/ajt.13535

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  6 in total

1.  MiR-200b in heme oxygenase-1-modified bone marrow mesenchymal stem cell-derived exosomes alleviates inflammatory injury of intestinal epithelial cells by targeting high mobility group box 3.

Authors:  Dong Sun; Huan Cao; Liu Yang; Ling Lin; Bin Hou; Weiping Zheng; Zhongyang Shen; Hongli Song
Journal:  Cell Death Dis       Date:  2020-06-25       Impact factor: 8.469

2.  Preemptive VAE-An Important Tool for Managing Blood Loss in MVT Candidates With PMT.

Authors:  Deeplaxmi P Borle; Samuel J Kesseli; Andrew S Barbas; Aparna S Rege; Deepak Vikraman; Ravindra Kadiyala; Charles Y Kim; Tony P Smith; Paul V Suhocki; Debra L Sudan
Journal:  Transplant Direct       Date:  2021-02-11

3.  Long-Term Signs of T Cell and Myeloid Cell Activation After Intestinal Transplantation With Cellular Rejections Contributing to Further Increase of CD16+ Cell Subsets.

Authors:  Nadja Stobutzki; Stephan Schlickeiser; Mathias Streitz; Katarina Stanko; Kim-Long Truong; Levent Akyuez; Katrin Vogt; Christine Appelt; Andreas Pascher; Olga Blau; Undine A Gerlach; Birgit Sawitzki
Journal:  Front Immunol       Date:  2019-05-07       Impact factor: 7.561

4.  Living Donor Intestinal Transplantation: Recipient Outcomes.

Authors:  Guosheng Wu; Chaoxu Liu; Xile Zhou; Long Zhao; Weitong Zhang; Mian Wang; Qingchuan Zhao; Tingbo Liang
Journal:  Ann Surg       Date:  2022-08-15       Impact factor: 13.787

5.  Multidrug-resistant organisms: A significant cause of severe sepsis in pediatric intestinal and multi-visceral transplantation.

Authors:  Alicia M Alcamo; Mira K Trivedi; Carly Dulabon; Christopher M Horvat; Geoffrey J Bond; Joseph A Carcillo; Michael Green; Marian G Michaels; Rajesh K Aneja
Journal:  Am J Transplant       Date:  2021-07-28       Impact factor: 8.086

6.  Liver-inclusive intestinal transplantation results in decreased alloimmune-mediated rejection but increased infection.

Authors:  Guosheng Wu; Ruy J Cruz
Journal:  Gastroenterol Rep (Oxf)       Date:  2017-12-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.